Skip to learning content
CLINORA
More
MRCP PART 1 · ENDOCRINOLOGY AND DIABETES

Endocrinology and diabetes questions
for MRCP Part 1.

Clinora has 373 endocrinology and diabetes single best answer questions covering 331 topics. Every question explains all five options, separates the key clue from what it means and what to do next, and links to its source. Try the 5 sample questions below, then practise more for free.

FREE SAMPLE QUESTIONS

Try 5 endocrinology and diabetes questions

Choose your answer, then open the explanation.

Question 1ComplicationsMedium

A 55-year-old man with type 2 diabetes for 10 years has never had retinal screening. Why is annual diabetic retinopathy screening important, and what is the most appropriate action now?

  1. AA single screening at diagnosis is sufficient for life
  2. BNo screening is needed unless he reports visual symptoms
  3. CScreening is only relevant for type 1 diabetes
  4. DArrange annual digital retinal photography screening promptly, as diabetic retinopathy can be asymptomatic until advanced and sight-threatening
  5. EScreening should be delayed until he develops proteinuria
Show answer and explanation

Answer: D Arrange annual digital retinal photography screening promptly, as diabetic retinopathy can be asymptomatic until advanced and sight-threatening

Diabetic retinopathy is usually asymptomatic until it is advanced. Sight-threatening maculopathy or proliferative disease can be present with normal vision, and by the time vision falls, treatment may only stabilise the damage rather than restore it. That is why everyone with diabetes aged 12 or over is invited to regular digital retinal photography through the NHS Diabetic Eye Screening Programme, whatever their symptoms. After 10 years of type 2 diabetes without screening, he should be referred into the programme now. Screening is annual in general. People with no retinopathy on two consecutive screens may be moved to 2-yearly screening, and anyone with referable disease goes to hospital eye services. Good glucose, blood pressure and lipid control all reduce progression.

Key clue
Long-standing type 2 diabetes with no prior retinal screening
What it means
Overdue diabetic retinopathy screening
What to do
Arrange prompt digital retinal photography screening and establish an annual screening schedule

Why the other options are less appropriate

  • A Retinopathy risk keeps rising with duration of diabetes, so screening is ongoing, not a one-off at diagnosis.
  • B Retinopathy is often silent until it is advanced. Waiting for symptoms risks missing treatable disease before permanent visual loss.
  • C Screening applies to everyone with diabetes aged 12 and over, type 1 or type 2.
  • E Nephropathy and retinopathy are screened for separately and in parallel. Waiting for proteinuria would delay eye screening without reason.

Source: NICE NG28 Type 2 diabetes in adults: management

Question 2Pituitary masses/hormone excessHard

A patient with a large pituitary macroadenoma has bitemporal hemianopia on visual field testing. Which anatomical relationship explains this visual field defect?

  1. ACompression of the optic chiasm, where fibres from the nasal retina (representing the temporal visual fields) decussate
  2. BCompression of the optic nerve alone, unilaterally
  3. CCompression of the occipital cortex
  4. DCompression of the oculomotor nerve
  5. ECompression of the optic tract only, sparing the chiasm
Show answer and explanation

Answer: A Compression of the optic chiasm, where fibres from the nasal retina (representing the temporal visual fields) decussate

The optic chiasm lies just above the pituitary fossa. At the chiasm, fibres from the nasal half of each retina cross to the opposite side. Nasal retina receives light from the temporal visual field, so pressure on these crossing fibres causes loss of both temporal fields: a bitemporal hemianopia. A pituitary adenoma pushes up from below and reaches the inferior crossing fibres first. Those carry the upper temporal fields, so the defect typically begins as a bitemporal upper quadrantanopia. A craniopharyngioma presses from above and tends to start in the lower quadrants. A visual field defect from a macroadenoma calls for urgent formal visual fields, MRI of the pituitary, a full pituitary hormone profile (including prolactin, with dilution to avoid the hook effect), and specialist assessment. A prolactinoma is usually treated with a dopamine agonist even when vision is affected; most other adenomas causing compression need surgery.

Key clue
Bitemporal hemianopia with a large pituitary mass
What it means
Optic chiasm compression from a pituitary macroadenoma
What to do
Arrange MRI pituitary, formal visual field assessment, and endocrine and neurosurgical referral for consideration of surgical decompression

Why the other options are less appropriate

  • B Pressure on one optic nerve causes loss of vision in that eye only, not a temporal field defect in both eyes.
  • C Occipital lesions cause a homonymous hemianopia, often sparing the macula, not a bitemporal defect.
  • D Oculomotor nerve compression causes ptosis, a 'down and out' eye and a dilated pupil, not a field defect.
  • E An optic tract lesion, behind the chiasm, causes a homonymous hemianopia on the opposite side.

Source: StatPearls: Neuroanatomy, Optic Chiasm

Question 3DiabetesMedium

A 34-year-old man presents to the acute medical unit with a 3-week history of polyuria, polydipsia, and an unintentional 6 kg weight loss. His body mass index is 22.4 kg/m². On examination, he is alert, his pulse is 88 beats/min, blood pressure is 124/78 mmHg, and respiratory rate is 16 breaths/min. Capillary blood glucose is 18.6 mmol/L and blood beta-hydroxybutyrate is 2.1 mmol/L. Venous blood gas shows pH 7.38, bicarbonate 23 mmol/L, and lactate 1.2 mmol/L. Which of the following is the most appropriate next step in management?

  1. ACommence metformin and arrange outpatient HbA1c testing
  2. BInitiate subcutaneous basal-bolus insulin and request anti-GAD and IA-2 antibodies
  3. CPrescribe a sulfonylurea and repeat capillary ketone testing in 48 hours
  4. DStart fixed-rate intravenous insulin infusion and 0.9% sodium chloride
  5. ECommence an SGLT2 inhibitor and arrange urgent pancreatic ultrasound
Show answer and explanation

Answer: B Initiate subcutaneous basal-bolus insulin and request anti-GAD and IA-2 antibodies

A lean adult with rapid weight loss, osmotic symptoms and a blood ketone level of 2.1 mmol/L has insulin deficiency, most likely from type 1 diabetes. NICE NG17 advises diagnosing type 1 diabetes on clinical grounds, noting that people with type 1 diabetes typically have one or more of ketosis, rapid weight loss, onset before 50 years, a BMI below 25 kg/m2 and a personal or family history of autoimmune disease. He does not have diabetic ketoacidosis: the JBDS criteria require ketones of 3.0 mmol/L or more, glucose above 11 mmol/L or known diabetes, and bicarbonate below 15 mmol/L and/or pH below 7.3. Without insulin, however, he is at high risk of progressing to it within days. He should start subcutaneous basal-bolus insulin the same day, with structured education, a blood ketone meter, sick-day rules and urgent follow-up by the specialist diabetes team. Islet autoantibodies such as anti-GAD and IA-2 support the classification, but insulin must not be delayed while waiting for results. A fixed-rate intravenous insulin infusion at 0.1 units/kg/hour is reserved for established DKA.

Key clue
34-year-old lean man with rapid weight loss, marked hyperglycaemia, and ketonaemia (2.1 mmol/L) without systemic acidoses (pH 7.38).
What it means
Features indicate severe insulin deficiency consistent with new-onset type 1 diabetes without established DKA.
What to do
Promptly initiate subcutaneous insulin therapy and request islet autoantibodies (anti-GAD/IA-2).

Why the other options are less appropriate

  • A Metformin does not correct insulin deficiency, and outpatient testing would leave a ketotic patient at risk of ketoacidosis within days.
  • C Sulfonylureas rely on residual beta-cell function and do not reliably prevent ketosis in insulin-deficient diabetes.
  • D A fixed-rate intravenous insulin infusion is for DKA, but his pH is 7.38 and bicarbonate 23 mmol/L, so the criteria are not met.
  • E SGLT2 inhibitors can precipitate euglycaemic ketoacidosis and are inappropriate in suspected type 1 diabetes with ketosis.

Source: Type 1 diabetes in adults: diagnosis and management (NICE NG17)

Question 4DiabetesEasy

A 52-year-old man attends his GP surgery complaining of a 6-week history of worsening thirst, nocturia (waking 3 times per night), and lethargy. He has no significant past medical history and takes no regular medications. His BMI is 31.4 kg/m². A random laboratory venous plasma glucose measurement returns at 12.6 mmol/L. Capillary blood ketones are 0.2 mmol/L. Which of the following is the most appropriate next step regarding his diagnostic status?

  1. AConfirm the diagnosis of diabetes mellitus immediately without requiring a second confirmatory blood sample
  2. BArrange an oral glucose tolerance test (OGTT) in 2 weeks before confirming diagnosis
  3. CRepeat the fasting plasma glucose within 14 days because a single reading is never diagnostic
  4. DRequest a 24-hour urinary glucose excretion test
  5. EMeasure serum fructosamine concentration to exclude laboratory error
Show answer and explanation

Answer: A Confirm the diagnosis of diabetes mellitus immediately without requiring a second confirmatory blood sample

Thirst, nocturia and lethargy are classic osmotic symptoms. With symptoms, one laboratory venous plasma glucose in the diabetic range is enough to diagnose diabetes. WHO criteria, used in the UK, are a fasting plasma glucose of 7.0 mmol/L or more, a random plasma glucose of 11.1 mmol/L or more, or an HbA1c of 48 mmol/mol (6.5%) or more. His random result of 12.6 mmol/L is above the 11.1 mmol/L threshold. A second test on another day is needed only when the patient has no symptoms. His ketones are 0.2 mmol/L, so there is no ketosis. With his age and BMI, type 2 diabetes is most likely. Measure HbA1c as a baseline. It is not needed for the diagnosis here, and it is unreliable in some groups, such as people with haemoglobinopathies or recent anaemia. Look for features of type 1 diabetes, such as rapid weight loss, ketosis, a young age or a low BMI. Then follow NICE NG28: structured education, lifestyle advice, cardiovascular risk assessment and metformin first line, adding an SGLT2 inhibitor if he has cardiovascular disease or high risk.

Key clue
Symptomatic man (polydipsia, nocturia) with venous fasting plasma glucose 12.6 mmol/L.
What it means
Unequivocal symptoms with fasting plasma glucose ≥7.0 mmol/L meets WHO/NICE criteria on a single sample.
What to do
Confirm the diagnosis of diabetes mellitus immediately.

Why the other options are less appropriate

  • B An OGTT is used when results are borderline. It adds nothing once a symptomatic patient has a clearly diagnostic glucose.
  • C A repeat test is needed only in someone without symptoms. This patient has classic osmotic symptoms.
  • D Glycosuria depends on the renal threshold, which varies between people. It is not part of the diagnostic criteria.
  • E Fructosamine reflects glycaemia over 2 to 3 weeks and is used for monitoring when HbA1c is unreliable. It is not a diagnostic test.

Source: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia

Question 5ThyroidEasy

A 29-year-old woman with newly diagnosed Graves disease was started on carbimazole 30 mg once daily 4 weeks ago. She presents to the emergency department with a 24-hour history of severe sore throat, painful swallowing, chills, and fever. On examination, her temperature is 38.8 °C, heart rate is 108 beats/min, and blood pressure is 118/74 mmHg. Examination of the oropharynx reveals erythematous tonsils with ulceration and exudate. What is the most appropriate immediate course of action?

  1. APrescribe oral amoxicillin and advise continuing carbimazole
  2. BHalve the carbimazole dose to 15 mg daily and review in 1 week
  3. CSwitch carbimazole to propylthiouracil immediately and discharge with analgesia
  4. DObtain throat swabs and await laboratory results before altering medications
  5. EStop carbimazole immediately and arrange an urgent full blood count
Show answer and explanation

Answer: E Stop carbimazole immediately and arrange an urgent full blood count

Fever, severe sore throat and mouth ulceration a few weeks after starting carbimazole must be treated as possible agranulocytosis until a full blood count proves otherwise. This rare reaction usually occurs in the first 3 months and is not dose-related. The carbimazole Summary of Product Characteristics tells patients to stop the drug and seek medical advice immediately if they develop these symptoms. A white cell count should be done straight away, and carbimazole should be stopped permanently if neutropenia is confirmed. A neutrophil count below 0.5 x 10^9/L with fever is neutropenic sepsis. NICE NG151 recommends broad-spectrum IV antibiotics, usually piperacillin with tazobactam, within 1 hour. Propylthiouracil can also cause agranulocytosis, and cross-reactivity has been reported, so it is not a safe substitute. Control hyperthyroid symptoms with a beta-blocker such as propranolol, and arrange specialist review for definitive treatment with radioactive iodine or thyroidectomy. Warn all patients about these symptoms at the start.

Key clue
Patient taking carbimazole for 4 weeks presenting with high fever, sore throat, and pharyngeal ulceration.
What it means
High clinical suspicion of thionamide-induced agranulocytosis.
What to do
Immediately discontinue carbimazole and obtain an urgent full blood count.

Why the other options are less appropriate

  • A Continuing carbimazole with oral antibiotics risks overwhelming sepsis if she has agranulocytosis. She needs an urgent blood count.
  • B Agranulocytosis is not dose-related, so halving the dose does not reduce the risk. The drug must be stopped.
  • C Propylthiouracil can also cause agranulocytosis, with reported cross-reactivity. Discharging her without a blood count is unsafe.
  • D Throat swab results take days. Waiting delays diagnosis and treatment of possible neutropenic sepsis.

Source: Carbimazole 20 mg tablets: Summary of Product Characteristics

That is 5 of 373. Carry on with endocrinology and diabetes in the practice bank, with progress tracking, flashcards and timed sessions.

Practise endocrinology and diabetes free →

Topics covered

Show all 331 endocrinology and diabetes topics
  • 11β-hydroxylase deficiency
  • 17-alpha-hydroxylase deficiency
  • A healed ulcer is still a high-risk foot
  • A mild TSH elevation, symptoms and age
  • A negative antibody panel leaves uncertainty
  • A non-surgical option for a symptomatic benign solid thyroid nodule
  • A normal radiograph cannot finish the bone-infection work-up
  • A renal transplant recipient with unstable diabetes
  • A safe alternative when CGM is declined
  • A severity score that records what matters
  • A solitary toxic thyroid nodule when surgery is chosen
  • Acromegaly
  • Acromegaly screening
  • Active Charcot neuroarthropathy
  • Additional testing in bilateral adrenal hyperplasia
  • Adrenal
  • Adrenal crisis
  • Adrenal crisis treatment
  • Adrenal crisis when confirmation is pending
  • Adrenal emergency injection preparedness
  • Adrenal insufficiency
  • Adrenal insufficiency mimicking SIADH
  • Adrenal insufficiency sick-day management
  • Adrenal insufficiency sick-day rules
  • Adrenal replacement during end-of-life care
  • Adrenal replacement in late pregnancy
  • Adult hypophosphatasia
  • Allowing an appropriate interval before repeat diagnostic TFTs
  • Alternative replacement when multiple daily hydrocortisone doses are unsuitable
  • Amenorrhoea
  • An indeterminate morning cortisol on a modern immunoassay
  • Androgen-secreting adrenocortical carcinoma
  • Antithyroid choice with previous pancreatitis
  • Antithyroid-drug agranulocytosis
  • Antithyroid-drug agranulocytosis and switching thionamides
  • Apparent mineralocorticoid excess
  • Arginine vasopressin deficiency
  • Assessing two adrenal lesions with different imaging appearances
  • Atherosclerotic disease changes initial diabetes therapy
  • Atypical femoral fracture
  • Autoantibody timing in suspected autoimmune diabetes
  • Autosomal dominant hypocalcaemia type 1
  • Autosomal dominant osteopetrosis type II
  • Avoiding serial thyroid peroxidase antibody measurements
  • Bariatric surgery assessment
  • Basal insulin choice after nocturnal hypoglycaemia
  • Benign adrenal incidentaloma
  • Bicarbonate in DKA
  • Bilateral adrenal masses
  • Bilateral primary aldosteronism treatment
  • Biotin interference
  • Bisphosphonates
  • Bisphosphonates are not routine Charcot treatment
  • BMI is not a type 1 exclusion test
  • Bone assessment in mild autonomous cortisol secretion
  • Borderline primary versus secondary clues
  • C-peptide several years after diagnosis
  • Carbohydrate counting before the full education course
  • Carcinoid heart disease
  • Carney complex
  • Central adiposity
  • CGM choice when predictive alerts matter
  • Choice after concordant parathyroid localisation
  • Choosing a reoperative parathyroid centre
  • Cinacalcet
  • Cinacalcet in primary hyperparathyroidism
  • Complete androgen insensitivity syndrome
  • Complications
  • Congenital leptin deficiency
  • Copeptin in polyuria-polydipsia syndromes
  • Corrected sodium during HHS treatment
  • Cortisol testing after an intra-articular steroid
  • Crisis before confirmation
  • Crisis fluid choice
  • Cushing disease localisation with a tiny pituitary lesion
  • Cyclic Cushing syndrome
  • Definitive treatment of Graves disease with compression
  • Delayed hypoglycaemia after activity
  • Desmopressin-associated hyponatraemia
  • Dexamethasone suppression and CYP3A4 induction
  • Dextrose during ongoing DKA treatment
  • Diabetes
  • Diabetic ketoacidosis
  • Diabetic kidney disease surveillance
  • Diabetic retinopathy
  • Discordant parathyroid localisation
  • Disorders of sex development
  • DKA during insulin-pump therapy
  • DKA resolution
  • Do not let a modest glucose reassure you
  • Do not stop insulin just because glucose has fallen
  • Dose during intercurrent stress
  • Dyslipidaemia
  • Early follow-up after radioactive iodine
  • Emergency injection preparedness
  • Euglycaemic diabetic ketoacidosis
  • Euglycaemic ketoacidosis with SGLT2 inhibition
  • Euthyroid thyroid nodule
  • Excluding phaeochromocytoma before an adrenal biopsy
  • Exercise when insulin is deficient
  • Existing prednisolone dose during intercurrent illness
  • Falling glucose is not resolved ketoacidosis
  • Familial combined hyperlipidaemia
  • Familial dysalbuminaemic hyperthyroxinaemia
  • Familial dysbetalipoproteinaemia
  • Familial glucocorticoid deficiency
  • Familial hypocalciuric hypercalcaemia
  • Frailty and medication harm
  • Frailty modifies the initial combination
  • Frailty with both metformin intolerance and SGLT2 risk
  • Frequency after medication change
  • Functional hypothalamic amenorrhoea and bone health
  • Gastroparesis testing during hyperglycaemia
  • Gestational transient thyrotoxicosis
  • Glucagon given but consciousness remains impaired
  • Glucocorticoid cover for adrenal surgery in MACS
  • Glucocorticoid withdrawal syndrome
  • Goitre red flags
  • Graves antibodies after definitive treatment in pregnancy
  • Graves disease confirmation
  • Graves disease with active eye disease
  • HbA1c invalid in haemolysis
  • HbA1c target without hypoglycaemia-inducing drugs
  • HNF1A-MODY
  • Hook effect in prolactinoma
  • Hungry bone syndrome
  • Hyperemesis with established adrenal insufficiency
  • Hyperosmolar hyperglycaemic state
  • Hypocalcaemia
  • Hypoglycaemia despite an initial education programme
  • Hypoglycaemia with unsafe swallow
  • Hypomagnesaemia-related hypocalcaemia
  • Hypopituitarism
  • Hypothalamic obesity after craniopharyngioma
  • Immune checkpoint inhibitor hypophysitis
  • Incretin duplication
  • Indeterminate adrenal imaging below four centimetres
  • Indeterminate cortisol
  • Individual education when group attendance is impossible
  • Individualising surgery for mild autonomous cortisol secretion
  • Initial therapy with established heart failure
  • Initial thyroid tests
  • Injection-site assessment in erratic glycaemic control
  • Inpatient prevention is more than an annual check
  • Insulin autoimmune syndrome
  • Insulinoma
  • Interpreting growth of an indeterminate adrenal lesion
  • Iron overload and secondary hypogonadism
  • Ischaemia changes the referral clock
  • Kallmann syndrome
  • Ketosis-prone diabetes
  • Lagging TSH after prolonged hypothyroidism
  • Levothyroxine initiation
  • Levothyroxine monitoring
  • Lithium-associated hyperparathyroidism
  • Long-acting glucocorticoid and final taper
  • Long-term drugs for toxic multinodular hyperthyroidism
  • Low morning cortisol
  • Macroprolactinaemia
  • Macroprolactinoma
  • Macroprolactinoma during pregnancy
  • Male hypogonadism
  • Marine–Lenhart syndrome
  • Mealtime analogue insulin timing
  • Medication-related osteonecrosis of the jaw
  • MEN2
  • MEN2A
  • Metabolic bone disease
  • Metformin intolerance and starting treatment
  • Metformin-associated vitamin B12 deficiency
  • Mild autonomous cortisol secretion
  • Mineralocorticoid over-replacement
  • Mineralocorticoid replacement in isolated secondary adrenal insufficiency
  • Monitoring after a completed antithyroid course
  • Monitoring after hemithyroidectomy
  • Monitoring central hypothyroidism
  • Monitoring hydrocortisone without routine cortisol curves
  • Multiple endocrine neoplasia type 1
  • Multiple endocrine neoplasia type 2B
  • Myxoedema coma
  • Myxoedema-coma cortisol cover
  • Negative TRAb
  • Non-classic 21-hydroxylase deficiency
  • Non-islet-cell tumour hypoglycaemia
  • Non-localising parathyroid ultrasound
  • Non-thyroidal illness syndrome
  • Normocalcaemic hyperparathyroidism
  • Obesity
  • Observation of a benign euthyroid goitre
  • Offloading an uncomplicated neuropathic plantar ulcer
  • Oral oestrogen and Cushing screening
  • Oral oestrogen and interpretation of serum cortisol
  • Osteogenesis imperfecta type I in an adult
  • Osteoporosis
  • Pancreatogenic diabetes
  • Parathyroid disorders
  • Parathyroid surgery
  • PCOS diagnosis in adolescence
  • PCOS-related anovulatory infertility
  • Persistent acromegaly
  • Persistent biochemical suppression
  • Persistent difficulty using a glucose sensor
  • Persistent disease after parathyroid surgery
  • Persistent hyperthyroidism after radioactive iodine
  • Persistent salt deficiency despite maximised fludrocortisone
  • Persistent symptoms
  • Phaeochromocytoma
  • Phaeochromocytoma alpha blockade
  • Phaeochromocytoma preoperative preparation
  • Phaeochromocytoma: alpha blockade before beta blockade
  • Pioglitazone and heart failure
  • Pituitary apoplexy surgical indication
  • Pituitary masses/hormone excess
  • Pituitary tumours
  • Polycystic ovary syndrome
  • Post-parathyroidectomy biochemical baseline
  • Posterior pituitary
  • Prednisolone taper and unnecessary routine conversion
  • Premature ovarian insufficiency
  • Preparing a morning cortisol during hydrocortisone withdrawal
  • Primary adrenal insufficiency
  • Primary adrenal insufficiency and renin
  • Primary aldosteronism
  • Primary aldosteronism lateralisation
  • Primary aldosteronism screen confounded by hypokalaemia
  • Primary generalised glucocorticoid resistance
  • Primary hyperparathyroidism
  • Primary hyperparathyroidism assessment
  • Primary hyperparathyroidism diagnosis
  • Primary hyperparathyroidism in pregnancy
  • Primary hypothyroidism
  • Primary ovarian insufficiency
  • Prolactinoma
  • Pseudohypoparathyroidism
  • Psychological stress and adrenal replacement
  • Quantifying impaired hypoglycaemia awareness
  • Reaccumulation of a benign thyroid cyst
  • Recognising glucocorticoid over-replacement
  • Recovery from glucocorticoid-induced adrenal insufficiency
  • Recurrent vomiting on sick day
  • Reflex ultrasound for thyrotoxicosis
  • Relowering sodium after dangerous overcorrection
  • Reopening endocrine assessment when comorbidities worsen
  • Repeated TSH above ten
  • Replacement physiology
  • Resistance to thyroid hormone beta
  • Retaining capillary testing when CGM is uncertain
  • Review the IV route early
  • Routine blood counts during antithyroid treatment
  • Routine monitoring of conservatively managed PHPT
  • Safety blood tests before thionamide treatment
  • Sample the infected wound, not the surface alone
  • Search for and treat the precipitant alongside DKA
  • Secondary hypothyroidism
  • Selecting adrenal imaging during pregnancy
  • Sequential therapy after anabolic osteoporosis treatment
  • Severe hypoglycaemia refractory to best usual care
  • Severe hypokalaemia in DKA
  • Severe primary dyslipidaemia
  • SGLT2 inhibitor sick-day interruption
  • Sheehan syndrome
  • Small-particle diet for diabetic gastroparesis
  • Somatostatinoma syndrome
  • Stable does not mean routine
  • Steroid emergency card
  • Steroid taper after prolonged use
  • Stone follow-up after successful parathyroid surgery
  • Stopping an unsuccessful symptomatic levothyroxine trial
  • Stopping surveillance after transient subclinical hyperthyroidism resolves
  • Struma ovarii causing thyrotoxicosis
  • Subclinical hyperthyroidism
  • Subclinical hypothyroidism
  • Surveillance of antibody-positive subclinical hypothyroidism
  • Suspected adrenal crisis
  • Symptomatic benign thyroid cyst
  • Symptomatic Paget's disease of bone
  • Target while taking a sulfonylurea
  • Tenofovir-associated Fanconi osteomalacia
  • Tertiary adrenal insufficiency
  • Test ketones urgently when a pregnant person with diabetes is unwell
  • Testing during acute illness
  • Testing while taking supraphysiological prednisolone
  • The best time for antibodies
  • Thyroglobulin antibody interference
  • Thyroid
  • Thyroid disease
  • Thyroid eye disease red flags
  • Thyroid storm
  • Thyroid storm with decompensated heart failure
  • Thyroid testing
  • Thyroid tests
  • Thyrotoxicosis
  • Thyrotoxicosis is not always synthesis
  • Thyroxine replacement with unrecognised adrenal insufficiency
  • Timing confirmation of parathyroid surgical success
  • Timing immediate-release hydrocortisone to the circadian rhythm
  • Treating hypoglycaemia while taking acarbose
  • Triphasic water-balance response after pituitary surgery
  • TSH receptor antibody in pregnancy
  • TSH-secreting pituitary adenoma
  • Tumour-induced osteomalacia
  • Type 1 diabetes and a metformin adjunct
  • Type 1 diabetes diagnosis
  • Type 1 diabetes technology
  • Type 1 glucose targets
  • Type 1 insulin regimen
  • Type 1 monitoring
  • Type 2 diabetes
  • Type 2 diabetes annual review
  • Type 2 diabetes technology
  • Type 2 diabetes with CKD
  • Type 2 diabetes with established ASCVD
  • Type 2 diabetes with frailty
  • Type 2 diabetes without a relevant comorbidity
  • Type 2 HbA1c
  • Type 2 HbA1c monitoring
  • Type 2 HbA1c validity
  • Type 2 individual targets
  • Type 2 initial treatment
  • Type 2 treatment aims
  • Type 2 treatment intensification
  • Type B insulin resistance syndrome
  • Uncertain diabetes classification
  • Unreliable HbA1c
  • Using two diabetes-specific antibodies
  • Very-high fracture risk
  • Visual impairment and insulin independence
  • Vitamin D in primary hyperparathyroidism
  • Weight loss despite established type 1 treatment
  • When thyroid ultrasound adds value in thyrotoxicosis
  • X-linked hypophosphataemia in adulthood

Other MRCP Part 1 specialties